Index of medicine substances

Econazole  •  Genito urinary system and sex hormones | Antiinfectives and antiseptics, excl. combinations with corticosteroids | Imidazole derivatives (G01AF05)

Eculizumab  •  Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Complement inhibitors (L04AJ01)

Edetate of sodium and calcium  •  Various | All other therapeutic products | All other therapeutic products | Antidotes (V03AB03)

Edoxaban  •  Blood and blood forming organs | Antithrombotic agents | Antithrombotic agents | Direct factor xa inhibitors (B01AF03)

Efalizumab  •  Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Selective immunosuppressants (L04AA21)

Efavirenz  •  Antiinfectives for systemic use | Direct acting antivirals | Non-nucleoside reverse transcriptase inhibitors (J05AG03)

Efavirenz + emtricitabine + tenofovir  •  Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations (J05AR06)

Efavirenz + emtricitabine + tenofovir disoproxil  •  Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations (J05AR06)

Efgartigimod alfa  •  Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Selective immunosuppressants (L04AA58)

Eflornithine  •  Dermatologicals | Other dermatological preparations | Other dermatological preparations | Other dermatologicals (D11AX)

Efmoroctocog alfa  •  Blood and blood forming organs | Vitamin k and other hemostatics | Blood coagulation factors (B02BD02)

Eftrenonacog alfa  •  Blood and blood forming organs | Vitamin k and other hemostatics | Blood coagulation factors (B02BD04)

Elacestrant  •  Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Anti-estrogens (L02BA04)

Elafibranor  •  Alimentary tract and metabolism | Bile therapy | Other drugs for bile therapy (A05AX06)

Elbasvir + grazoprevir  •  Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections (J05AP54)

Electrolytes  •  Blood and blood forming organs | I.v. solutions | Solutions affecting the electrolyte balance (B05BB01)

Eletriptan  •  Nervous system | Antimigraine preparations | Selective serotonin (5HT1) agonists (N02CC06)

Eliglustat  •  Alimentary tract and metabolism | Other alimentary tract and metabolism products | Other alimentary tract and metabolism products | Various alimentary tract and metabolism products (A16AX10)

Elosulfase alfa  •  Alimentary tract and metabolism | Other alimentary tract and metabolism products | Other alimentary tract and metabolism products | Enzymes (A16AB12)

Elranatamab  •  Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Other monoclonal antibodies and antibody drug conjugates (L01FX32)

Eltrombopag  •  Blood and blood forming organs | Vitamin k and other hemostatics | Other systemic hemostatics (B02BX05)

Elvitegravir + cobicistat + emtricitabine + tenofovir  •  Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations (J05AR18)

Emedastine  •  Sensory organs | Decongestants and antiallergics | Other antiallergics (S01GX06)

Emicizumab  •  Blood and blood forming organs | Vitamin k and other hemostatics | Other systemic hemostatics (B02BX06)

Empagliflozin  •  Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Sodium-glucose co-transporter 2 (SGLT2) inhibitors (A10BK03)

Empagliflozin + metformin  •  Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Combinations of oral blood glucose lowering drugs (A10BD20)

Emtricitabine  •  Antiinfectives for systemic use | Direct acting antivirals | Nucleoside and nucleotide reverse transcriptase inhibitors (J05AF09)

Emtricitabine + rilpivirine + tenofovir alafenamide  •  Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations (J05AR19)

Emtricitabine + tenofovir  •  Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations (J05AR03)

Emtricitabine + tenofovir alafenamide  •  Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations (J05AR17)